<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）的股票在週三發佈的報告中被 Guggenheim 的股票分析師重申了 “買入” 評級，Benzinga 報道。他們目前對這家生物製藥公司的股票設定了 72.00 美元的目標價。Guggenheim 的目標價表明該股票當前價格有 24.82% 的潛在上漲空間。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>2 只值得增持的巴菲特股票——以及 1 只需要拋售的股票</li>
</ul>
<p>其他幾位研究分析師也對該公司發表了評論。富國銀行在 2 月 6 日的研究報告中重申了 “跑贏大盤” 評級，並將百時美施貴寶的目標價從 55.00 美元上調至 60.00 美元。Leerink Partners 在 1 月 13 日的研究報告中將百時美施貴寶的目標價從 54.00 美元上調至 60.00 美元，並給予該股票 “跑贏大盤” 評級。美國銀行在 12 月 15 日的研究報告中將百時美施貴寶的評級從 “中性” 上調至 “買入”，並將其目標價從 52.00 美元上調至 61.00 美元。花旗集團在 2 月 6 日的研究報告中將百時美施貴寶的目標價從 60.00 美元上調至 64.00 美元，並給予該股票 “中性” 評級。最後，Piper Sandler 在 2 月 23 日的報告中重申了 “增持” 評級，並將百時美施貴寶的目標價從 66.00 美元上調至 75.00 美元。九位投資分析師對該股票給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 61.35 美元。</p>
<p><strong>獲取我們關於百時美施貴寶的最新股票報告</strong></p>
<h2>百時美施貴寶的價格表現</h2>
<ul>
<li>為什麼 GRAIL 股票可能成為生物技術領域的下一個重大突破</li>
</ul>
<p>週三，BMY 的股票開盤價為 57.68 美元。該公司的 50 日簡單移動平均線為 59.51 美元，200 日簡單移動平均線為 52.94 美元。該股票的市值為 1177.7 億美元，市盈率為 16.72，市盈增長比率為 0.17，貝塔值為 0.27。百時美施貴寶的 1 年低點為 42.52 美元，1 年高點為 62.89 美元。該公司的債務與股本比率為 2.32，流動比率為 1.26，速動比率為 1.14。</p>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近一次發佈季度財報是在 2 月 5 日。該生物製藥公司報告本季度每股收益為 1.26 美元，低於分析師共識預期的 1.65 美元，差額為 0.39 美元。百時美施貴寶的股本回報率為 69.65%，淨利潤率為 14.64%。該公司本季度的收入為 125 億美元，而分析師預期為 122.4 億美元。在去年同期，該公司每股收益為 1.67 美元。該公司的季度收入同比增長 1.3%。百時美施貴寶已將其 2026 財年的指導目標設定為每股收益 6.050-6.350 美元。整體來看，分析師預測百時美施貴寶今年將發佈每股收益 6.74 美元。</p>
<h2>內部人士下注</h2>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>在相關消息中，執行副總裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。該股票以平均價格 61.67 美元出售，總價值為 1,850,100.00 美元。交易完成後，該執行副總裁直接持有公司股票 159,248 股，價值 9,820,824.16 美元。這代表其持股比例減少了 15.85%。該出售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。當前 0.09% 的股票由公司內部人士持有。</p>
<h2>對百時美施貴寶的對沖基金看法</h2>
<p>對沖基金最近對該公司的持倉進行了調整。J. Derek Lewis &amp; Associates Inc.在第四季度購買了百時美施貴寶的新股份，價值約 432,000 美元。Osbon Capital Management LLC 在第四季度獲得了百時美施貴寶的新頭寸，價值約 55,000 美元。World Investment Advisors 在第四季度將其在百時美施貴寶的持股增加了 14.1%。World Investment Advisors 目前持有該生物製藥公司 64,471 股股票，價值 3,478,000 美元，在此期間又增持了 7,977 股。Nalls Sherbakoff Group LLC 在第四季度購買了百時美施貴寶的新頭寸，價值約 92,000 美元。最後，Larry Mathis Financial Planning LLC 在第四季度獲得了百時美施貴寶的新頭寸，價值 427,000 美元。對沖基金和其他機構投資者持有該公司 76.41% 的股票。</p>
<h2>百時美施貴寶公司簡介</h2>
<p>（獲取免費報告）</p>
<p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括研究與開發、臨牀開發、製造和商業化多個治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
<p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過百時美施貴寶</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

百時美施貴寶

<p>Guggenheim 重申了對百時美施貴寶（NYSE:BMY）的 “買入” 評級，目標價為 72.00 美元，意味着潛在上漲幅度為 24.82%。其他分析師也提高了他們的目標價，普遍評級為 “持有”，平均目標價為 61.35 美元。該股票開盤價為 57.68 美元，市值為 1177.7 億美元。百時美施貴寶在上個季度報告的每股收益為 1.26 美元，低於預期，但收入為 125 億美元，超出預期。公司對 2026 財年的指導為每股收益在 6.050-6.350 之間</p>

<p>Bristol Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its &#34;buy&#34; rating reaffirmed by stock analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They presently have a $72.00 price target on the biopharmaceutical company's stock. Guggenheim's target price indicates a potential upside of 24.82% from the stock's current price.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）的股票在週三發佈的報告中被 Guggenheim 的股票分析師重申了 “買入” 評級，Benzinga 報道。他們目前對這家生物製藥公司的股票設定了 72.00 美元的目標價。Guggenheim 的目標價表明該股票當前價格有 24.82% 的潛在上漲空間。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只值得增持的巴菲特股票——以及 1 只需要拋售的股票</li>
</ul>
</div><p>Several other research analysts have also commented on the company. Wells Fargo &amp; Company restated an &#34;outperform&#34; rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, February 6th. Finally, Piper Sandler reiterated an &#34;overweight&#34; rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $61.35.</p>
<div class="lb-trans"><p>其他幾位研究分析師也對該公司發表了評論。富國銀行在 2 月 6 日的研究報告中重申了 “跑贏大盤” 評級，並將百時美施貴寶的目標價從 55.00 美元上調至 60.00 美元。Leerink Partners 在 1 月 13 日的研究報告中將百時美施貴寶的目標價從 54.00 美元上調至 60.00 美元，並給予該股票 “跑贏大盤” 評級。美國銀行在 12 月 15 日的研究報告中將百時美施貴寶的評級從 “中性” 上調至 “買入”，並將其目標價從 52.00 美元上調至 61.00 美元。花旗集團在 2 月 6 日的研究報告中將百時美施貴寶的目標價從 60.00 美元上調至 64.00 美元，並給予該股票 “中性” 評級。最後，Piper Sandler 在 2 月 23 日的報告中重申了 “增持” 評級，並將百時美施貴寶的目標價從 66.00 美元上調至 75.00 美元。九位投資分析師對該股票給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 61.35 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於百時美施貴寶的最新股票報告</strong></p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶的價格表現</h2>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能成為生物技術領域的下一個重大突破</li>
</ul>
</div><p>Shares of BMY opened at $57.68 on Wednesday. The firm has a 50-day simple moving average of $59.51 and a two-hundred day simple moving average of $52.94. The stock has a market cap of $117.77 billion, a PE ratio of 16.72, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.</p>
<div class="lb-trans"><p>週三，BMY 的股票開盤價為 57.68 美元。該公司的 50 日簡單移動平均線為 59.51 美元，200 日簡單移動平均線為 52.94 美元。該股票的市值為 1177.7 億美元，市盈率為 16.72，市盈增長比率為 0.17，貝塔值為 0.27。百時美施貴寶的 1 年低點為 42.52 美元，1 年高點為 62.89 美元。該公司的債務與股本比率為 2.32，流動比率為 1.26，速動比率為 1.14。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business's revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近一次發佈季度財報是在 2 月 5 日。該生物製藥公司報告本季度每股收益為 1.26 美元，低於分析師共識預期的 1.65 美元，差額為 0.39 美元。百時美施貴寶的股本回報率為 69.65%，淨利潤率為 14.64%。該公司本季度的收入為 125 億美元，而分析師預期為 122.4 億美元。在去年同期，該公司每股收益為 1.67 美元。該公司的季度收入同比增長 1.3%。百時美施貴寶已將其 2026 財年的指導目標設定為每股收益 6.050-6.350 美元。整體來看，分析師預測百時美施貴寶今年將發佈每股收益 6.74 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>In related news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。該股票以平均價格 61.67 美元出售，總價值為 1,850,100.00 美元。交易完成後，該執行副總裁直接持有公司股票 159,248 股，價值 9,820,824.16 美元。這代表其持股比例減少了 15.85%。該出售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。當前 0.09% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>對百時美施貴寶的對沖基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. J. Derek Lewis &amp; Associates Inc. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $432,000. Osbon Capital Management LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $55,000. World Investment Advisors boosted its holdings in shares of Bristol Myers Squibb by 14.1% in the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company's stock valued at $3,478,000 after acquiring an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $92,000. Finally, Larry Mathis Financial Planning LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $427,000. Hedge funds and other institutional investors own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。J. Derek Lewis &amp; Associates Inc.在第四季度購買了百時美施貴寶的新股份，價值約 432,000 美元。Osbon Capital Management LLC 在第四季度獲得了百時美施貴寶的新頭寸，價值約 55,000 美元。World Investment Advisors 在第四季度將其在百時美施貴寶的持股增加了 14.1%。World Investment Advisors 目前持有該生物製藥公司 64,471 股股票，價值 3,478,000 美元，在此期間又增持了 7,977 股。Nalls Sherbakoff Group LLC 在第四季度購買了百時美施貴寶的新頭寸，價值約 92,000 美元。最後，Larry Mathis Financial Planning LLC 在第四季度獲得了百時美施貴寶的新頭寸，價值 427,000 美元。對沖基金和其他機構投資者持有該公司 76.41% 的股票。</p>
</div><h2>Bristol Myers Squibb Company Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括研究與開發、臨牀開發、製造和商業化多個治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過百時美施貴寶</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

百時美施貴寶公司（NYSE:BMY）獲得古根海姆的買入評級